西妥昔单抗 meaning in Chinese

cetuximab
erbitux

The use of cetuximab for colorectal cancer was highest in france and the united states and lowest in finland
法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。
Two of the drugs have already been approved for clinical use : cetuximab and celecoxib , while the third , gm6001 , is still experimental
其中两种药物已经批准应用于临床：西妥昔单抗和塞来考昔，另一种加贝酯则仍在实验中。
The largest disparities were in the use of the new colorectal and lung cancer drugs : bevacizumab , cetuximab , erlotinib and pemetrexed , the study found
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
Conclusion : these results confirm the high prognostic value of kras mutations on response to cetuximab and survival in metastatic crc patients treated with cetuximab
结论：这些结果证实了： kras突变对于转移性crc患者使用西妥昔单抗治疗时对西妥昔单抗耐药情况和生存期具有很高的预测价值。